Alexandre Le Guilcher

Sarah Matta, Mathieu Lamard, Philippe Zhang et al.

Numerous Deep Learning (DL) classification models have been developed for a large spectrum of medical image analysis applications, which promises to reshape various facets of medical practice. Despite early advances in DL model validation and implementation, which encourage healthcare institutions to adopt them, a fundamental questions remain: how can these models effectively handle domain shift? This question is crucial to limit DL models performance degradation. Medical data are dynamic and prone to domain shift, due to multiple factors. Two main shift types can occur over time: 1) covariate shift mainly arising due to updates to medical equipment and 2) concept shift caused by inter-grader variability. To mitigate the problem of domain shift, existing surveys mainly focus on domain adaptation techniques, with an emphasis on covariate shift. More generally, no work has reviewed the state-of-the-art solutions while focusing on the shift types. This paper aims to explore existing domain generalization methods for DL-based classification models through a systematic review of literature. It proposes a taxonomy based on the shift type they aim to solve. Papers were searched and gathered on Scopus till 10 April 2023, and after the eligibility screening and quality evaluation, 77 articles were identified. Exclusion criteria included: lack of methodological novelty (e.g., reviews, benchmarks), experiments conducted on a single mono-center dataset, or articles not written in English. The results of this paper show that learning based methods are emerging, for both shift types. Finally, we discuss future challenges, including the need for improved evaluation protocols and benchmarks, and envisioned future developments to achieve robust, generalized models for medical image classification.

Philippe Zhang, Weili Jiang, Yihao Li et al.

Age-related Macular Degeneration (AMD) is a prevalent eye condition affecting visual acuity. Anti-vascular endothelial growth factor (anti-VEGF) treatments have been effective in slowing the progression of neovascular AMD, with better outcomes achieved through timely diagnosis and consistent monitoring. Tracking the progression of neovascular activity in OCT scans of patients with exudative AMD allows for the development of more personalized and effective treatment plans. This was the focus of the Monitoring Age-related Macular Degeneration Progression in Optical Coherence Tomography (MARIO) challenge, in which we participated. In Task 1, which involved classifying the evolution between two pairs of 2D slices from consecutive OCT acquisitions, we employed a fusion CNN network with model ensembling to further enhance the model's performance. For Task 2, which focused on predicting progression over the next three months based on current exam data, we proposed the Patch Progression Masked Autoencoder that generates an OCT for the next exam and then classifies the evolution between the current OCT and the one generated using our solution from Task 1. The results we achieved allowed us to place in the Top 10 for both tasks. Some team members are part of the same organization as the challenge organizers; therefore, we are not eligible to compete for the prize.

Gwenolé Quellec, Mathieu Lamard, Bruno Lay et al.

The purpose of this study is to evaluate the performance of the OphtAI system for the automatic detection of referable diabetic retinopathy (DR) and the automatic assessment of DR severity using color fundus photography. OphtAI relies on ensembles of convolutional neural networks trained to recognize eye laterality, detect referable DR and assess DR severity. The system can either process single images or full examination records. To document the automatic diagnoses, accurate heatmaps are generated. The system was developed and validated using a dataset of 763,848 images from 164,660 screening procedures from the OPHDIAT screening program. For comparison purposes, it was also evaluated in the public Messidor-2 dataset. Referable DR can be detected with an area under the ROC curve of AUC = 0.989 in the Messidor-2 dataset, using the University of Iowa's reference standard (95% CI: 0.984-0.994). This is better than the only AI system authorized by the FDA, evaluated in the exact same conditions (AUC = 0.980). OphtAI can also detect vision-threatening DR with an AUC of 0.997 (95% CI: 0.996-0.998) and proliferative DR with an AUC of 0.997 (95% CI: 0.995-0.999). The system runs in 0.3 seconds using a graphics processing unit and less than 2 seconds without. OphtAI is safer, faster and more comprehensive than the only AI system authorized by the FDA so far. Instant DR diagnosis is now possible, which is expected to streamline DR screening and to give easy access to DR screening to more diabetic patients.